Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Código QR

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Etienne Giroux Leprieur,1,2 Vincent Fallet,3,4 Jacques Cadranel,3,4 Marie Wislez3,4 1Respiratory Diseases and Thoracic Oncology Department, APHP-Ambroise Paré Hospital, Boulogne-Billancourt, France; 2EA4340 Laboratory, UVSQ, Paris-Saclay University, France; 3Respiratory Diseases Departmen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giroux Leprieur E, Fallet V, Cadranel J, Wislez M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	ALK rearrangement crizotinib non-small cell lung carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2059dbbae5964960a6fa029619e4506f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain RK, et al.
Publicado: (2017)

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
por: Liang L, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma
por: Takamori S, et al.
Publicado: (2020)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Caiyu Lin, et al.
Publicado: (2021)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
por: Shuluan Li, et al.
Publicado: (2021)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018)

ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors
por: Elena Corral de la Fuente, et al.
Publicado: (2021)

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock AB, et al.
Publicado: (2020)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
por: Hao-chuan Ma, et al.
Publicado: (2021)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
por: Mehta A, et al.
Publicado: (2020)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu VW, et al.
Publicado: (2020)

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Ling Peng, et al.
Publicado: (2021)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Chi‐Hao Wu, et al.
Publicado: (2021)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
por: Zhu VW, et al.
Publicado: (2019)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu VW, et al.
Publicado: (2018)

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
por: Tomasz Marjanski, et al.
Publicado: (2021)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte G, et al.
Publicado: (2019)

Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
por: Daugrois Camille, et al.
Publicado: (2021)

Manejo clínico y terapéutico de un tumor fibroso pleural con translocación de ALK
por: Patricia Cruz-Castellanos, et al.
Publicado: (2021)

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
por: Wen Dong, et al.
Publicado: (2021)

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
por: Adriana Petrazzuolo, et al.
Publicado: (2021)

Molecular genetic portrait of non-small cell lung cancer in Tambov region: regional experience
por: N. A. Ognerubov, et al.
Publicado: (2020)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Tobias Dechow, et al.
Publicado: (2021)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
por: Christabel Wilson, et al.
Publicado: (2017)

Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
por: Zhang S, et al.
Publicado: (2021)

Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
por: Anna M. Wulf, et al.
Publicado: (2021)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà T
Publicado: (2017)

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
por: Rossi G, et al.
Publicado: (2017)

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
por: Gadgeel S, et al.
Publicado: (2019)

Resistance to Aflatoxin Accumulation in Maize Mediated by Host-Induced Silencing of the <i>Aspergillus flavus</i> Alkaline Protease (<i>alk</i>) Gene
por: Olanike Omolehin, et al.
Publicado: (2021)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel D, et al.
Publicado: (2021)

Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
por: Thakur MK, et al.
Publicado: (2017)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)

Analysis of gene expression changes associated with human carcinoma-associated fibroblasts in non-small cell lung carcinoma
por: Wu,Xiaofen, et al.
Publicado: (2017)

The Dual Effect of the BMP9–ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?
por: Blanca Ayuso-Íñigo, et al.
Publicado: (2021)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa S, et al.
Publicado: (2021)